Our Science

TransCode Therapeutics believes it has overcome the greatest barrier to harnessing RNA technology for cancer treatment by devising an elegant solution for the transport of powerful RNA therapeutics to targeted cancer cells through our TTX delivery platform.

Our strategy seeks to leverage a nanoparticle that has been extensively used in humans for imaging by repurposing it to deliver synthetic RNAs or oligonucleotides (oligos for short) to cancer cells. The nanocarrier can be chemically tuned to pre-designed specifications to deliver therapeutic oligonucleotides to an RNA target in tumors and metastases without compromising its integrity.

​These iron oxide nanoparticles have an excellent clinical safety record of low toxicity and low immunogenicity established over the course of the past 30 years.

​The figure below illustrates the numerous benefits and opportunities of this platform, backed by nearly two decades of R&D optimization.​

Yoo B, et al. J Biomed Nanotechnol. 2014;10(6):1114-1122.; Yigit MV, et al. Pharm Res. 2012;29(5):1180-1188.; Weissleder R, et al. Radiology. 1991;181(1):245-249.